Time filter

Source Type

Grambach, Austria

Bateman R.J.,University of Washington | Aisen P.S.,University of California at San Diego | De Strooper B.,Vlaams Institute for Biotechnology | De Strooper B.,Catholic University of Leuven | And 7 more authors.
Alzheimer's Research and Therapy

Autosomal-dominant Alzheimer's disease has provided significant understanding of the pathophysiology of Alzheimer's disease. The present review summarizes clinical, pathological, imaging, biochemical, and molecular studies of autosomal-dominant Alzheimer's disease, highlighting the similarities and differences between the dominantly inherited form of Alzheimer's disease and the more common sporadic form of Alzheimer's disease. Current developments in autosomal-dominant Alzheimer's disease are presented, including the international Dominantly Inherited Alzheimer Network and this network's initiative for clinical trials. Clinical trials in autosomal-dominant Alzheimer's disease may test the amyloid hypothesis, determine the timing of treatment, and lead the way to Alzheimer's disease prevention. © 2011 BioMed Central Ltd. Source

Bolognesi M.L.,University of Bologna | Chiriano G.,International School for Advanced Studies | Bartolini M.,University of Bologna | Mancini F.,University of Bologna | And 10 more authors.
Journal of Medicinal Chemistry

Eight monomeric congeners, related to the multitarget lead candidate memoquin, were prepared and evaluated at multiple targets to determine their profile against Alzheimer's disease. 2-4 bind to AChE with similar low nanomolar affinities and function as effective inhibitors of amyloid aggregation. The most potent monovalent ligand 2 also inhibits BACE-1 in vitro and APP metabolism in primary chicken telencephalic neurons. (Figure presented) © 2011 American Chemical Society. Source

Rosini M.,University of Bologna | Simoni E.,University of Bologna | Bartolini M.,University of Bologna | Soriano E.,Institute Quimica Organica General CSIC | And 8 more authors.

Inspired by the concept of bivalent ligands, we prepared a small set of analogues of the drug candidate dimebon. They were shown to inhibit AChE, Aβ42 aggregation, and NMDA receptor activation to a greater extent than dimebon. Some of these compounds also enhanced the survival of chicken neurons under apoptosis-inducing conditions. Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. Source

Discover hidden collaborations